Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2020

Open Access 01-12-2020 | Metastasis | Research

Downregulation of miR-484 is associated with poor prognosis and tumor progression of gastric cancer

Authors: Ying Li, Yusong Liu, Jie Yao, Rui Li, Xiaocheng Fan

Published in: Diagnostic Pathology | Issue 1/2020

Login to get access

Abstract

Background

Gastric cancer is one of the most common cancers leading to high cancer mortality. MicroRNA-484 (miR-484) has been evaluated as a biomarker for various types of cancers. The subject of this study is to investigate the functional role of miR-484 in gastric cancer.

Methods

The expression of miR-484 in gastric cancer was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR) assay. Kaplan-Meier survival and Cox regression analyses were employed to explore the prognostic significance of miR-484 in gastric cancer. The functional role of miR-484 in gastric cancer was determined by CCK-8 and Transwell assays.

Results

The results showed that miR-484 was significantly downregulated in gastric cancer tissues and cell lines. The downregulation of miR-484 was closely related to differentiation, lymph node metastasis, TNM stage, and poor prognosis. Cox regression analyses demonstrated that miR-484 was an independent prognosis indicator for gastric cancer patients. Additionally, the downregulation of miR-484 enhanced cell proliferation, migration, and invasion in gastric cancer cells.

Conclusion

These data demonstrated that miR-484 can serve as a potential prognostic biomarker and therapeutic target for gastric cancer and it may be involved in the progression of gastric cancer.
Literature
1.
Futami T, Kawase T, Mori K, Asaumi M, Kihara R, Shindoh N, et al. Identification of a novel oncogenic mutation of FGFR4 in gastric cancer. Sci Rep. 2019;9(1):14627.CrossRef
2.
3.
Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.CrossRef
4.
Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release. 2013;172(3):962–74.CrossRef
5.
Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102–14.CrossRef
6.
Li J, Zou X. MiR-652 serves as a prognostic biomarker in gastric cancer and promotes tumor proliferation, migration, and invasion via targeting RORA. Cancer biomarkers. 2019;undefined(undefined):1–9.
7.
Wang S, Gao B, Yang H, Liu X, Wu X, Wang W. MicroRNA-432 is downregulated in cervical cancer and directly targets FN1 to inhibit cell proliferation and invasion. Oncol Lett. 2019;18(2):1475–82.PubMedPubMedCentral
8.
Wang L, Zhao Y, Xiong W, Ye W, Zhao W, Hua Y. MicroRNA-449a Is Downregulated in Cervical Cancer and Inhibits Proliferation, Migration, and Invasion. Oncol Res Treat. 2019;42(11):1–7.CrossRef
9.
Han X, Du C, Chen Y, Zhong X, Wang F, Wang J, et al. Overexpression of miR-939-3p predicts poor prognosis and promotes progression in lung cancer. Cancer Biomark. 2019;25(4):325–32.CrossRef
10.
Wang X, Zhou Z, Zhang T, Wang M, Xu R, Qin S, et al. Overexpression of miR-664 is associated with poor overall survival and accelerates cell proliferation, migration and invasion in hepatocellular carcinoma. Oncotargets Ther. 2019;12(undefined):2373–81.CrossRef
11.
Wang R, Li G, Zhuang G, Sun S, Song Z. Overexpression of microRNA-423-3p indicates poor prognosis and promotes cell proliferation, migration, and invasion of lung cancer. Diagn Pathol. 2019;14(1):53.CrossRef
12.
Ji R, Zhang X, Gu H, Ma J, Wen X, Zhou J, et al. MiR-374a-5p: a new target for diagnosis and drug resistance therapy in gastric Cancer. Mol Ther Nucleic Acids. 2019;18:320–31.CrossRef
13.
Wei C, Gao JJ. Downregulated miR-383-5p contributes to the proliferation and migration of gastric cancer cells and is associated with poor prognosis. PeerJ. 2019;7:e7882.CrossRef
14.
Feng C, She J, Chen X, Zhang Q, Zhang X, Wang Y, et al. Exosomal miR-196a-1 promotes gastric cancer cell invasion and metastasis by targeting SFRP1. Nanomedicine (Lond). 2019;14:1743–5889..CrossRef
15.
Li T, Ding ZL, Zheng YL, Wang W. MiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting Apaf-1 associated with the suppression of apoptosis. Biomed Pharmacother. 2017;96:153–64.CrossRef
16.
Hu Y, Xie H, Liu Y, Liu W, Liu M, Tang H. MiR-484 suppresses proliferation and epithelial-mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells. Cancer Cell Int. 2017;17:–36.
17.
Ye F-G, Song C-G, Cao Z-G, Xia C, Chen D-N, Chen L, et al. Cytidine Deaminase Axis modulated by miR-484 differentially regulates cell proliferation and Chemoresistance in breast Cancer. Cancer Res. 2015;75(7):1504–15.CrossRef
18.
Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 2012;106(4):740–7.CrossRef
19.
Treece AL, Duncan DL, Tang W, Elmore S, Morgan DR, Dominguez RL, et al. Gastric adenocarcinoma microRNA profiles in fixed tissue and in plasma reveal cancer-associated and Epstein-Barr virus-related expression patterns. Lab Investig. 2016;96(6):661–71.CrossRef
20.
Zare A, Ahadi A, Larki P, Omrani MD, Zali MR, Alamdari NM, et al. The clinical significance of miR-335, miR-124, miR-218 and miR-484 downregulation in gastric cancer. Mol Biol Rep. 2018;45(6):1587–95.CrossRef
21.
22.
Hata A, Kashima R. Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol. 2016;51(3):121–34.CrossRef
23.
Tavazoie S, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos P, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147–52.CrossRef
24.
Liu H, Ma L, Wang J. Overexpression of miR-25 is associated with progression and poor prognosis of cholangiocarcinoma. Exp Ther Med. 2019;18(4):2687–94.PubMedPubMedCentral
25.
Wei F, Wang M, Li Z, Wang Y, Zhou Y. MiR593 inhibits proliferation and invasion and promotes apoptosis in nonsmall cell lung cancer cells by targeting SLUGassociated signaling pathways. Mol Med Rep. 2019;20(undefined):5172–82.PubMedPubMedCentral
26.
Min C, Zhang A, Qin J. Increased expression of miR-601 is associated with poor prognosis and tumor progression of gastric cancer. Diagn Pathol. 2019;14(1):107.CrossRef
27.
Hu JY, Yi W, Wei X, Zhang MY, Xu R, Zeng LS, et al. MiR-601 is a prognostic marker and suppresses cell growth and invasion by targeting PTP4A1 in breast cancer. Biomed Pharmacother. 2016;79:247–53.CrossRef
28.
Hu X, Zhang M, Miao J, Wang X, Huang C. MiRNA-4317 suppresses human gastric cancer cell proliferation by targeting ZNF322. Cell Biol Int. 2018;42(8):923–30.CrossRef
29.
Wang R, Sun Y, Yu W, Yan Y, Qiao M, Jiang R, et al. Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT. J Exp Clin Cancer Res. 2019;38(1):20.CrossRef
30.
Fan D, Ren B, Yang X, Liu J, Zhang Z. Upregulation of miR-501-5p activates the wnt/β-catenin signaling pathway and enhances stem cell-like phenotype in gastric cancer. J Exp Clin Cancer Res. 2016;35(1):177.CrossRef
31.
Wang F, Lv P, Liu X, Zhu M, Qiu X. MicroRNA-214 enhances the invasion ability of breast cancer cells by targeting p53. Int J Mol Med. 2015;35(5):1395–402.CrossRef
32.
Carter JV, O'Brien SJ, Burton JF, Oxford BG, Stephen V, Hallion J, et al. The microRNA-200 family acts as an oncogene in colorectal cancer by inhibiting the tumor suppressor RASSF2. Oncol Lett. 2019;18(4):3994–4007.PubMedPubMedCentral
33.
Merhautova J, Hezova R, Poprach A, Kovarikova A, Radova L, Svoboda M, et al. MiR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed Res Int. 2015:941980.
34.
Zhang Q, Li X, Chen Z. LncRNA H19 promotes epithelial-mesenchymal transition (EMT) by targeting miR-484 in human lung cancer cells. J Cell Biochem. 2018;119(6):4447–57.CrossRef
35.
Guo X, Han T, Hu P, Zhu C, Wang Y, Chang S. Five microRNAs in serum as potential biomarkers for prostate cancer risk assessment and therapeutic intervention. Int Urol Nephrol. 2018;50(12):2193–200.CrossRef
36.
Wang S, Wang W, Han X, Wang Y, Ge Y, Tan Z. Dysregulation of miR484-TUSC5 axis takes part in the progression of hepatocellular carcinoma. J Biochem. 2019;166(3):271–9.CrossRef
37.
Xie S, Ge Q, Wang X, Sun X, Kang Y. Long non-coding RNA ZFAS1 sponges miR-484 to promote cell proliferation and invasion in colorectal cancer. Cell Cycle. 2018;17(2):154–61.CrossRef
38.
Yi R, Feng J, Yang S, Huang X, Liao Y, Hu Z, et al. MiR-484/MAP2/c-Myc-positive regulatory loop in glioma promotes tumor-initiating properties through ERK1/2 signaling. J Mol Histol. 2018;49(2):209–18.CrossRef
Metadata
Title
Downregulation of miR-484 is associated with poor prognosis and tumor progression of gastric cancer
Authors
Ying Li
Yusong Liu
Jie Yao
Rui Li
Xiaocheng Fan
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2020
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-020-00946-8

Other articles of this Issue 1/2020

Diagnostic Pathology 1/2020 Go to the issue

Research

Accuracy and efficiency of an artificial intelligence tool when counting breast mitoses

Case Report

Fibro-adipose vascular anomaly (FAVA): three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway

Research

Markers of immune activation: novel biomarkers to predict the early-warning indicator of patients with papillary thyroid carcinoma

Case Report

46, XY disorder of sex development (DSD) complicated by a serous borderline tumor of the ovary: a case report and review of the literature

Commentary

Targeted remodeling of breast cancer and immune cell homing niches by exosomal integrins

Short report

An economical Nanopore sequencing assay for human papillomavirus (HPV) genotyping